Structure of a Thyrotropin Receptor Monoclonal Antibody Variable Region Provides Insight into Potential Mechanisms for its Inverse Agonist Activity

Abstract

Background:

The high constitutive, or ligand-independent, activity of the thyrotropin receptor (TSHR) is of clinical importance in some thyroid conditions, particularly well-differentiated thyroid carcinoma remnants following incomplete ablative therapy (surgery and radioiodine). Under these conditions, even total suppression of TSH by thyroid hormone administration does not fully reduce TSHR activity, a driver of thyrocyte growth.

Methods:

CS-17 is a murine monoclonal antibody that has inverse agonist activity in that it suppresses TSHR constitutive activity. This study crystallized the CS-17 Fab and determined its atomic structure at a resolution of 3.4 Å.

Results:

In silico docking of this structure to that of the TSHR extracellular domain was accomplished by targeting to TSHR residue tyrosine 195 (Y195) known to contribute to the CS-17 epitope. High affinity interaction between these two molecules, primarily by the CS-17 immunoglobulin heavy chain, was validated by energetic analysis (K_D of 8.7 × 10^–11 M), as well as by previously obtained data on a number of individual TSHR amino acids in three regions whose mutagenesis reduced CS-17 binding as detected by flow cytometry.

Conclusions:

Structural insight at atomic resolution of a TSHR antibody with inverse agonist activity opens the way for the development of a molecule with therapeutic potential, particularly in thyroid carcinoma. For this purpose, CS-17 will require “humanization” by substitution of its constant region (Fc component). In addition, with its epitope defined, the CS-17 affinity can be increased further by mutagenesis of selected amino acids in its heavy- and light-chain complementarity determining regions.

Introduction

Thyroid hormone homeostasis is essential for normal growth and development. Reduced or excessive thyroid hormone levels can lead to severe metabolic consequences affecting all organs of the body. Homeostasis is maintained by pituitary secretion of thyrotropin (TSH) in a negative feedback loop by thyroid hormones secreted by the thyroid. The TSH receptor (TSHR), a class A member of the G-protein coupled receptors (GPCR) with a large extracellular domain (ECD)—reviewed in Rapoport et al. (1) and Vassart et al. (2)—mediates the action of TSH and therefore plays a pivotal role in the pathophysiological regulation of thyroid function (reviewed in Vassart and Dumont) (3). An unusual property of the TSHR relative to the closely related follicle-stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHR) is its high constitutive, or ligand-independent, activity (4), a property partially suppressed by the TSHR ECD itself (5). In this sense, the TSHR ECD can be considered a tethered inverse agonist, converted by TSH into a more potent agonist (6).

High TSHR constitutive activity is of clinical importance in thyroid carcinoma, the great majority of which are well differentiated (7). It has been recognized for >60 years that thyroid hormone suppression of TSH secretion can reduce the post-ablative (surgery or radioiodine) recurrence of thyroid carcinoma both locally and distantly (8,9). Because moderate or complete suppression of TSH secretion requires supraphysiological doses of thyroxine (T4), awareness in recent years of deleterious consequences has led to guidelines restricting this approach to incomplete removal of thyroid carcinoma, a common outcome (10). However, even complete TSH suppression does not reduce TSHR constitutive activity—hence the current interest in the use of TSHR inverse agonists to suppress this activity in concert with physiological T4 replacement following thyroid ablation.

Previously, a mouse monoclonal antibody, CS-17, was generated with inverse agonist activity (11). The present study reports the crystal structure of the CS-17 Fab molecule. In silico docking of this structure with that of the TSHR ECD provides insight into potential mechanisms by which CS-17 constrains the high level of TSHR constitutive activity.

Methods

CS-17 Fab purification

Monoclonal antibody CS-17, an IgG2a, is one of a panel of TSHR monoclonal antibodies (mAb) generated in the authors' laboratory by immunizing BALB/c mice by intramuscular injection of an adenovirus expressing the human TSHR A-subunit, as reported previously (11). Murine SP-2/0 hybridoma cells were transferred to QED Biosciences (San Diego, CA) for ascite generation in SCID mice lacking endogenous mouse immunoglobulin G (IgG). CS-17 IgG was extracted from the ascites using Protein G Hi-Trap columns (GE Healthcare, Piscataway NJ) following which the IgG was digested and Fab purified using the ImmunoPure Fab Preparation kit (Pierce, Rockford, IL). The nucleotide and amino acid sequences of the heavy and light chains of CS-17 Fab have been submitted to GeneBank (accession numbers MH036357 for H chain and MH036358 for the light chain). CS-17 Fab amino acid residues are shown in Figure 1.

FIG. 1.

Primary amino acid sequence of the CS-17 heavy (H) chain and light (L) chain variable regions. The complementarity determining regions (CDRs) are in bold. FR, framework region.

CS-17 Fab crystals and X-ray diffraction

CS-17 Fab, in 20 mM of Tris, pH 7.4, 150 mM of NaCl, and at a concentration of 14 mg/mL, was crystallized using the hanging drop vapor diffusion method. An equal volume of well solution (0.1 M of HEPES, pH 7.5, 0.3 M of ammonium citrate, and 20% PEG 3350) was added to CS-17 Fab and equilibrated over well solution at 18°C. Crystals were cryoprotected by soaking in well solution containing 35% PEG 3350 followed by flash-freezing in liquid nitrogen. Initially, low-resolution diffraction data were collected in-house using a Rigaku Micromax 007HF X-ray diffractometer with an R-Axis IV++ detector and processed/scaled with XDS/XSCALE (12). Then, crystals were also sent to the Stanford Synchrotron Radiation Lightsource (SSRL) facility to obtain high-resolution data. The crystals diffracted to a maximum resolution of 3.4 Å. The structure was solved by molecular replacement with Phaser (13) using the heavy and light chains of the Fab for monoclonal OKT3 (PDB ID: 1SY6) (14) as a search model. The crystallographic model was built using Coot (15) and refined using Phenix (16) and BUSTER (17).

Docking of the CS-17 atomic structure to the TSHR ECD

ZDOCK (18) was used for in silico docking of CS-17 to the TSHR ECD. The structure of the latter was based on the known structure of TSHR residues 22–260 (largely the LRD; structure database 3G04 and 2XWT) (19,20), together with TSHR residues 261–410 modeled on the crystal structure of the FSHR hinge region (structure data base 4AY9) (21), as described by Kreuchwig et al. (22,23) (http://ssfa-gphr.de).

CS-17 binding energetics

The energetics of the CS-17/TSHR ECD complex were analyzed by PRODIGY (24,25).

Results

Crystal structure of the CS-17 Fab

Crystals of purified CS-17 Fab (Fig. 2) were subjected to X-ray diffraction analysis. Despite analysis of multiple sets of CS-17 crystals generated over a period of nearly two years, and repeated efforts to collect high-resolution data at the SSRL facility, only moderate resolution of its atomic structure (3.4 Å) was obtained. Nonetheless, the overall structure for CS-17 Fab was determined using molecular replacement. The backbone conformation of all six CDR loops was determined unambiguously. Due to resolution limit, neither solvents nor side chains could be determined with greater accuracy. Side chains were built using COOT (26) and optimized by molecular simulations using Desmond (Schrodinger, Inc., San Diego, CA). Data collection and refinement statistics are shown in Table 1. The final structure of Fab CS-17 is shown in Figure 3.

FIG. 2.

Selection of CS-17 crystals, from which some were subjected to Synchrotron X-ray diffraction analysis. Crystal birefringence under polarizing light is shown in the right panel.

FIG. 3.

Molecular structure of the CS-17 Fab in complex with the thyrotropin receptor (TSHR) extracellular domain (ECD). The TSHR is shown in green; the L chain of CS-17 Fab is in magenta and the H chain in blue. The ECD structure was based on the crystal structure of TSHR residues 22–260 (19,20), together with TSHR residues 261–410 modeled on the crystal structure of the FSHR hinge region (21), as described by Kreuchwig et al. (22,23) (see Methods).

Table 1.

Data Collection and Refinement Statistics for the CS-17 TSHR Monoclonal Antibody Fab

Data collection
Space group	P1
Cell dimensions:
a, b, c (Å)	53.72, 108.92, 151.58
α, β, γ (°)	100.262, 90.416, 90.028
Resolution (Å)	3.4 (3.48–3.40)
R _sym	0.183 (0.505)
I/σI	4.88 (1.93)
Completeness (%)	95.6 (96.0)
Redundancy	2.2 (2.2)
Refinement
Resolution (Å)	19.65–3.40
Number of reflections	44428
R _work/R _free (%)	32.0/33.9
Total number of atoms modeled	1634
Number of protein atoms modeled	13216
Number of water molecules modeled	0
B factors	77.54
rms deviations
Bond lengths (Å)	0.007
Bond angles (°)	0.90

Values in parentheses are for highest-resolution shell.

TSHR, thyrotropin receptor; rms, root mean square.

Docking of the CS-17 Fab to the TSHR ECD

To facilitate in silico docking, extensive studies had previously provided information regarding the CS-17 epitope. First, the immunogen for generating CS-17 was the recombinant human TSHR A-subunit (amino acids 22–289; residues 1–21 being the signal peptide) (27,28). Second, flow cytometric studies using chimeric receptors involving substitution of human TSHR segments with the corresponding region of the closely related rat LHR localized a major portion of the CS-17 epitope to be downstream of TSHR residue 260 (11). Taken together, these observations localized a significant portion of the CS-17 epitope to lie between residues 261 and 289. Third, based on the observation that CS-17 recognized the human but not the porcine TSH holoreceptor, individual substitution of six non-homologous human TSHR amino acid residues with its porcine counterpart within this region identified human TSHR Y195 as having a significant influence on CS-17 binding, while that of a control TSHR antibody to a distant location was unaffected (29) (Fig. 4). Consequently, in silico docking of the atomic structure of the CS-17 Fab with the TSHR ECD was performed, selecting TSHR Y195 as a target.

FIG. 4.

TSHR ECD mutations previously observed to reduce CS-17 binding as detected by flow cytometry. TSH holoreceptors with Y195H and Q235/S243P (dual mutation) and Y195H/Q235/S243P (triple mutation) were stably (and clonally) expressed on the surface of intact Chinese hamster ovary (CHO) cells (29). Included as negative control for CS-17 recognition is normal mouse immunoglobulin G (IgG; Con) and mouse monoclonal antibody (mAb) 4C1, whose epitope is distant from CS-17, as a positive control. The horizontal arrows depict the degree of reduction in CS-17 binding compared to binding of 4C1; the triple mutation totally abrogates CS-17 binding whereas 4C1 recognition is unaffected. For the N198Q, T200A, and T273/R274V (dual) mutations, TSHR holoreceptors were transiently (non-clonally) expressed, and the TSHR null cells in the pool serve as negative controls (30). The dotted ovals depict the loss of CS-17 binding relative to that for another control TSHR antibody, 2C11. The panels in this figure were selected from an extensive series of mutations, the majority of which had no effect on CS-17 binding and are reproduced from the following manuscripts with permission from the Oxford University Press: Chen CR et al., Identification of key amino acid residues in a thyrotropin receptor monoclonal antibody epitope provides insight into its inverse agonist and antagonist properties. Endocrinology 2008;149(7):3427–3434; and Chen CR et al. A monoclonal antibody with thyrotropin (TSH) receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain. Endocrinology 2009;150(7):3401–3408.

Of the top 10 predicted models, cluster #5 of the CS-17 Fab TSHR ECD complex (Fig. 3) was validated on the basis of energetic analysis taken together with the experimental data described above. The interface of this complex was predicted by PRODIGY (18,19) to involve a very high affinity interaction, with a DeltaG (kcal/mol) of −13.7 and a K_D of 8.7 × 10^–11 M. Individual TSHR amino acids whose experimental mutagenesis reduced CS-17 binding were located in three regions:

(1) Besides a Y195H mutation, mutation of closely related residues, N198Q and T200A, also had a major effect on CS-17 binding to the TSH holoreceptor expressed on the surface of Chinese hamster ovary (CHO) cells (30) (Fig. 4). These functional effects are supported by the in silico docking analysis indicating contact of TSHR Y195 with CS-17 L chain H91, TSHR N198 with CS-17 H chain V105, and TSHR K201 with CS-17 H chain residues Y101, E99, and S31 (Fig. 5A and Table 2). Of note, all CS-17 contact residues are within the Fab complementarity determining regions.

(2) Docking analysis predicted interaction between TSHR H271 and CS-17 H chain Y60 (Fig. 5B and Table 2). This information is consistent with the dual mutation of adjacent TSHR amino acid residues T273L and R274V completely abrogating CS-17 binding (30) (Fig. 4).

(3) A third region in the docking analysis involved TSHR K244 and G245 interacting with L chain S92 and H chain N59, respectively (Fig. 5C and Table 2). These data are consistent with the TSHR dual Q235Y, S243P mutations on CS-17 binding (29). Though small on their own, these mutations together with the Y195H mutation synergistically abrogated CS-17 binding (Fig. 4). The segment of the TSHR between Q235 and S243 is a single strand (shown in yellow). Proline residues introduce a fixed bend in the secondary structure of a protein. Therefore, mutation of S243 to a proline immediately adjacent to K244 and G245, as well as the Q235Y mutation, will alter the position of K244 and G245 in this strand.

FIG. 5.

Detail of CS-17 binding to TSHR ECD in segments in which mutagenesis of the latter reduced this interaction (Fig. 4). The numerous other interfaces between these molecules are listed in Table 1. (A) TSHR mutated residues Y195, N198, and T200. Contact occurs between TSHR Y195 with CS-17 L chain H91 and TSHR N198 with CS-17 H chain V105. Although TSHR T200 (green sphere) does not interact with CS-17, its mutation will affect the position of adjacent residue K201 which does interface with CS-17 H chain residues Y101, E99, and S31. (B) Interaction between TSHR H271 and CS-17 H chain Y60. TSHR residues T273 and R274 do not interact with CS-17 (green spheres). However, their mutation would alter the position of contact residue H271, which is closely related on the same strand and is consistent with a severe reduction in CS-17 binding. (C) TSHR K244 and G245 interact with L chain S92 and H chain N59, respectively. These data are consistent with mutation of adjacent residue S243 (green sphere), which does not interact with CS-17. A S243P substitution would introduce a bend and alter the position of adjacent residues K244 and G245. Although not close to the CS-17 binding surface, Q235 (green sphere) and S243 are on the same strand (shown in yellow), and the latter could contribute to a lesser degree on the reduction in CS-17 binding.

Table 2.

CS-17 TSHR ECD Hydrogen-Bonded Interactions

TSHR-ECD	CS-17	Distance (Å)
178E	H30T, H31S	2.8; 3.6
195Y	L91H	3.0
201K	H31S, H99E	2.9; 2.8^*	(Salt bridge^*)
203D	H55N	3.0
222G	L91H	3.3	(Backbone)
224V	L93Y, L90Y	3.0, 3.1	(Backbone)
225Y	H104R	3.0
227G	H50Y	3.3	(Backbone)
245G	H59N	3.1
271H	H60Y	3.2

Asterisk indicates a salt bridge.

Putative contacts between CS-17 heavy (H) and light (L) chains and the TSHR ECD were determined using CONTACT (CCP4) (51).

Discussion

GPCR are the target of many therapeutic agents that function as antagonists or inverse agonists, some with both properties (reviewed in Bond and Ijzerman) (31). Although the great majority of inverse agonists are small molecules isolated by screening synthetic molecule libraries, mAb also provide therapeutic opportunities—reviewed in Webb et al. (32), Mujic-Delic et al. (33), and Jacobson (34). Unlike small molecules, very few mAb with inverse agonist activity have been generated, such as to the beta2-adrenergic (35), M2 muscarinic acetylcholine (36), melanocortin-4 (37), and CXCR4 chemokine (38) receptors.

An inverse agonist to the TSHR would be of value in a number of clinical conditions, particularly thyroid cancer in which TSHR constitutive activity can drive thyrocyte growth even when its natural ligand, TSH, is totally suppressed by thyroid hormone administration (see Introduction). Both small molecule (39,40) and mAb (11,41) inverse agonists for the TSHR have been generated or isolated. Pending further structural refinement, the former are either of relatively low affinity or have only partial specificity when tested against the closely related LHR and FSHR. Because small molecule allosteric modulators permeate the plasma membrane and insert into a pocket in the hepta-helical transmembrane domain, there is also the possibility of unanticipated clinical side effects, given the vast number of known and orphan receptors in the GPCR family. On the other hand, the advantages of an inverse agonist TSHR mAb are its high affinity and specificity for a very large receptor ECD absent in most GPCR.

Solving the atomic structure of the CS-17 Fab was not straightforward, with the highest resolution being 3.4°Å, despite three submissions of multiple crystals for synchrotron analysis. Nevertheless, this resolution was sufficient for in silico docking with the TSHR ECD. Based on previous mutagenesis locating TSHR Y195 as an important contributor to the CS-17 epitope, the CS-17 Fab structure to the TSHR ECD (22,23) was targeted using ZDOCK (see Methods). The validity of the interaction between CS-17 and the TSHR ECD was supported by previously obtained experimental data (see Results), in particular partial or total inhibition of CS-17 by mutation of TSHR residues (in addition to Y195) N198, T200, and the dual mutations of T273, R274, Q235, and S243. Further support was provided by the very high calculated affinity of the in silico interaction, comparable to the functional effect of CS-17 in the nanomolar range in suppressing constitutive activity of the recombinant TSHR expressed on CHO cell monolayers (11).

Characterizing the CS-17 epitope provides insight into how this antibody exerts its inverse agonist activity. The TSHR hinge region is the region involved in coupling TSH (the physiological ligand) binding to the transmembrane domain. Two critical residues in the TSHR hinge involved in receptor activation are Y385 (42,43) and S281 (44,45), reviewed in Kleinau et al. (46). Upon TSH binding, upward movement of TSHR Y385 (equivalent residue Y335 in the FSHR) into a ligand pocket is associated with flexion in the hinge region leading to signal transduction (21,47) (Fig. 6). Mutation of S281 leads to near full receptor activation, comparable to that effected by TSH and much greater than ligand independent constitutive activity. In contrast to ligand activation, the TSHR ECD (5,6), in particular the hinge region (48), partially suppresses constitutive activity. Inverse agonist CS-17 further accentuates this constraint. Based on the present data, it is proposed that CS-17 binding to the TSHR ECD flexes the hinge region in the opposite direction to the natural ligand, increasing the ectodomain suppression of constitutive activity (Fig. 6). The majority of the CS-17 contact residues are in the rigid TSHR leucine rich repeat domain, but CS-17 H chain Y60 also contacts TSHR amino acid residue H271 in the flexible hinge region, thereby clamping this hinge configuration. Another possible mechanism for CS-17 inverse agonist activity may relate to its potential impact on the association or dissociation of TSHR multimers on the cell surface. Indeed, there is evidence (though controversial) that activation by agonists (TSH and thyroid stimulating antibodies) influences the extent of TSHR multimerization, reviewed in Kleinau et al. (49). In addition, TSHR ligand independent constitutive activity is also related to negative cooperativity, the latter a function of receptor multimerization (50). Future studies will be required to determine whether CS-17 influences TSHR multimerization, such as by using bioluminescence resonance energy transfer.

FIG. 6.

Proposed mechanism of CS-17 inverse agonist activity. The TSHR ECD comprises a leucine-rich repeat domain (LRD) whose crystal structure is known (13,14) and a hinge region modeled on the closely related FSHR (21). The membrane spanning domain, modeled on rhodopsin, and the TSHR holoreceptor as a unit is from Kreuchwig et al. (22,23). Upward movement of TSHR residue Y385 following ligand binding flexes the hinge region (arrow) and transduces receptor signaling via the transmembrane domain (TMD) (21,47). Residue S281 is a key interface with the TMD and its mutation to numerous amino acids leads to receptor activation comparable to TSH (44,45). The major footprint of CS-17 is on the TSHR LRD, but it also binds to H271 in the hinge regions. It is proposed that CS-17's inverse agonist activity occurs by flexing the hinge region in the direction opposite to the ligand TSH (arrow).

In summary, solving the atomic structure of a TSHR antibody with inverse agonist activity opens the way to development of a molecule with therapeutic potential in certain thyroid conditions, particularly well-differentiated thyroid carcinoma metastases remaining after conventional ablative therapy. For this purpose, CS-17 will require “humanization” by substitution of its Fc component. In addition, with its epitope defined, the CS-17 affinity can be increased further by mutagenesis of selected amino acids in its H and L chain complementarity determining regions.

Footnotes

Acknowledgments

This work was supported by National Institutes of Health Grant DK19289 (B.R. until 2016), DK54684 (S.M.M.), and the Molecular Therapeutics Core Facility, Cedars- Sinai Research Institute. A pdb file for CS-17 docked to the TSHR ECD can be sent upon request.

Author Disclosure Statement

No competing financial interests exist.

References

Rapoport

, Chazenbalk

, Jaume

, McLachlan

. 1998. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev, 19:673–716.

Vassart

, Pardo

, Costagliola

. 2004. A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci, 29:119–126.

Vassart

, Dumont

. 1992. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev, 13:596–611.

Van Sande

, Swillens

, Gerard

, Allgeier

, Massart

, Vassart

, Dumont

. 1995. In Chinese hamster ovary K1 cells dog and human thyrotropin receptors activate both the cyclic AMP and the phosphatidylinositol 4,5-bisphosphate cascades in the presence of thyrotropin and the cyclic AMP cascade in its absence. Eur J Biochem, 229:338–343.

Zhang

, Tong

, Fremont

, Chen

, Narayan

, Puett

, Weintraub

, Szkudlinski

. 2000. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. Endocrinology, 141:3514–3517.

Vlaeminck-Guillem

, Ho

, Rodien

, Vassart

, Costagliola

. 2002. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol, 16:736–746.

Pathak

, Leslie

, Klonisch

, Nason

. 2013. The changing face of thyroid cancer in a population-based cohort. Cancer Med, 2:537–544.

Crile

Jr . 1957. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth. Cancer, 10:1119–1137.

Mazzaferri

, Kloos

. 2001. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 86:1447–1463.

10.

Haugen

, Alexander

, Bible

, Doherty

, Mandel

, Nikiforov

, Pacini

, Randolph

, Sawka

, Schlumberger

, Schuff

, Sherman

, Sosa

, Steward

, Tuttle

, Wartofsky

. 2016. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.

11.

Chen

, McLachlan

, Rapoport

. 2007. Suppression of thyrotropin receptor constitutive activity by a monoclonal antibody with inverse agonist activity. Endocrinology, 148:2375–2382.

12.

Kabsch

. 2010. XDS. Acta Crystallogr D Biol Crystallogr, 66:125–132.

13.

McCoy

, Grosse-Kunstleve

, Adams

, Winn

, Storoni

, Read

. 2007. Phaser crystallographic software. J Appl Crystallogr, 40:658–674.

14.

Kjer-Nielsen

, Dunstone

, Kostenko

, Ely

, Beddoe

, Mifsud

, Purcell

, Brooks

, McCluskey

, Rossjohn

. 2004. Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3. Proc Natl Acad Sci U S A, 101:7675–7680.

15.

Emsley

, Lohkamp

, Scott

, Cowtan

. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr, 66:486–501.

16.

Adams

, Afonine

, Bunkoczi

, Chen

, Davis

, Echols

, Headd

, Hung

, Kapral

, Grosse-Kunstleve

, McCoy

, Moriarty

, Oeffner

, Read

, Richardson

, Terwilliger

, Zwart

. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr, 66:213–221.

17.

Bricogne

. 1993. Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives. Acta Crystallogr D Biol Crystallogr, 49:37–60.

18.

Pierce

, Wiehe

, Hwang

, Kim

, Vreven

, Weng

. 2014. ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers. Bioinformatics, 30:1771–1773.

19.

Sanders

, Chirgadze

, Sanders

, Baker

, Sullivan

, Bhardwaja

, Bolton

, Reeve

, Nakatake

, Evans

, Richards

, Powell

, Miguel

, Blundell

, Furmaniak

, Smith

. 2007. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid, 17:395–410.

20.

Sanders

, Young

, Sanders

, Kabelis

, Baker

, Sullivan

, Evans

, Clark

, Wilmot

, Hu

, Roberts

, Powell

, Nunez

, Furmaniak

, Rees

. 2011. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol, 46:81–99.

21.

Jiang

, Liu

, Chen

, Fischer

, Sriraman

, Yu

, Arkinstall

, He

. 2012. Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. Proc Natl Acad Sci U S A, 109:12491–12496.

22.

Kreuchwig

, Kleinau

, Krause

. 2013. Research resource: novel structural insights bridge gaps in glycoprotein hormone receptor analyses. Mol Endocrinol, 27:1357–1363.

23.

Kreuchwig

, Kleinau

, Kreuchwig

, Worth

, Krause

. 2011. Research resource: Update and extension of a glycoprotein hormone receptors web application. Mol Endocrinol, 25:707–712.

24.

Vangone

, Bonvin

. 2015. Contacts-based prediction of binding affinity in protein–protein complexes. Elife, 4:e07454.

25.

Xue

, Rodrigues

, Kastritis

, Bonvin

, Vangone

. 2016. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. Bioinformatics, 32:3676–3678.

26.

Emsley

, Cowtan

. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr, 60:2126–2132.

27.

Chazenbalk

, Jaume

, McLachlan

, Rapoport

. 1997. Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera. J Biol Chem, 272:18959–18965.

28.

Chazenbalk

, McLachlan

, Pichurin

, Rapoport

. 2001. A prion-like shift between two conformational forms of a recombinant thyrotropin receptor A-subunit module: purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies. J Clin Endocrinol Metab, 86:1287–1293.

29.

Chen

, McLachlan

, Rapoport

. 2008. Identification of key amino acid residues in a thyrotropin receptor monoclonal antibody epitope provides insight into its inverse agonist and antagonist properties. Endocrinology, 149:3427–3434.

30.

Chen

, McLachlan

, Rapoport

. 2009. A monoclonal antibody with thyrotropin (TSH) receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain. Endocrinology, 150:3401–3408.

31.

Bond

, Ijzerman

. 2006. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci, 27:92–96.

32.

Webb

, Handel

, Kretz-Rommel

, Stevens

. 2013. Opportunities for functional selectivity in GPCR antibodies. Biochem Pharmacol, 85:147–152.

33.

Mujic-Delic

, de Wit

, Verkaar

, Smit

. 2014. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. Trends Pharmacol Sci, 35:247–255.

34.

Jacobson

. 2015. New paradigms in GPCR drug discovery. Biochem Pharmacol, 98:541–555.

35.

Peter

, Eftekhari

, Billiald

, Wallukat

, Hoebeke

. 2003. scFv single chain antibody variable fragment as inverse agonist of the beta2-adrenergic receptor. J Biol Chem, 278:36740–36747.

36.

Peter

, Wallukat

, Tugler

, Maurice

, Roegel

, Briand

, Hoebeke

. 2004. Modulation of the M2 muscarinic acetylcholine receptor activity with monoclonal anti-M2 receptor antibody fragments. J Biol Chem, 279:55697–55706.

37.

Peter

, Nicholson

, Heydet

, Lecourt

, Hoebeke

, Hofbauer

. 2007. Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo . Am J Physiol Regul Integr Comp Physiol, 292:R2151–R2158.

38.

Jahnichen

, Blanchetot

, Maussang

, Gonzalez-Pajuelo

, Chow

, Bosch

, De Vrieze

, Serruys

, Ulrichts

, Vandevelde

, Saunders

, De Haard

, Schols

, Leurs

, Vanlandschoot

, Verrips

, Smit

. 2010. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A, 107:20565–20570.

39.

Neumann

, Huang

, Eliseeva

, Titus

, Thomas

, Gershengorn

. 2010. A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology, 151:3454–3459.

40.

Van Koppen

, de Gooyer

, Karstens

, Plate

, Conti

, van Achterberg

, van Amstel

, Brands

, Wat

, Berg

, Lane

, Miltenburg

, Timmers

. 2012. Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor. Br J Pharmacol, 165:2314–2324.

41.

Sanders

, Evans

, Betterle

, Sanders

, Bhardwaja

, Young

, Roberts

, Wilmot

, Richards

, Kiddie

, Small

, Platt

, Summerhayes

, Harris

, Reeve

, Coco

, Zanchetta

, Chen

, Furmaniak

, Rees Smith

. 2008. A human monoclonal autoantibody to the thyrotropin receptor with thyroid stimulating blocking activity. Thyroid, 18:735–746.

42.

Kosugi

, Ban

, Akamizu

, Kohn

. 1991. Site-directed mutagenesis of a portion of the extracellular domain of the rat thyrotropin receptor important in autoimmune thyroid disease and nonhomologous with gonadotropin receptors. Relationship of functional and immunogenic domains. J Biol Chem, 266:19413–19418.

43.

Costagliola

, Panneels

, Bonomi

, Koch

, Many

, Smits

, Vassart

. 2002. Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO J, 21:504–513.

44.

Kopp

, Jameson

, Roe

. 1997. Congenital nonautoimmune hyperthyroidism in a nonidentical twin caused by a sporadic germline mutation in the thyrotropin receptor gene. Thyroid, 7:765–770.

45.

Duprez

, Parma

, Costagliola

, Hermans

, Van Sande

, Dumont

, Vassart

. 1997. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett, 409:469–474.

46.

Kleinau

, Neumann

, Gruters

, Krude

, Biebermann

. 2013. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev, 34:691–724.

47.

Jiang

, Fischer

, Chen

, McKenna

, Liu

, Sriraman

, Yu

, Goutopoulos

, Arkinstall

, He

. 2014. Evidence for follicle-stimulating hormone receptor as a functional trimer. J Biol Chem, 289:14273–14282.

48.

Mizutori

, Chen

C-R

, McLachlan

, Rapoport

. 2008. The thyrotropin receptor hinge region is not simply a scaffold for the leucine-rich domain but contributes to ligand binding and signal transduction. Mol Endocrinol, 22:1171–1182.

49.

Kleinau

, Worth

, Kreuchwig

, Biebermann

, Marcinkowski

, Scheerer

, Krause

. 2017. Structural–functional features of the thyrotropin receptor: a class A G-protein-coupled receptor at work. Front Endocrinol (Lausanne), 8:86.

50.

Zoenen

, Urizar

, Swillens

, Vassart

, Costagliola

. 2012. Evidence for activity-regulated hormone-binding cooperativity across glycoprotein hormone receptor homomers. Nat Commun, 3:1007.

51.

Collaborative Computational Project

. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr, 50:760–763.